RALEIGH, N.C.--Pfizer Poultry Health is offering U.S. poultry producers
a new option to optimize protection against one of the poultry
industry’s most costly diseases, coccidiosis.
Inovocox® EM1 is specially formulated to fight coccidiosis - the
intestinal parasitic disease with an annual estimated global economic
impact exceeding $3 billion.
The new formulation accompanies the vaccine Inovocox® - launched in
early 2009 - as the first and only coccidiosis vaccines specifically
licensed and designed for in ovo administration.
Both vaccines contain Eimeria acervulina and E. tenella
but, unlike its relative, Inovocox EM1 contains only one strain of E.
maxima, meaning there is a reduced risk of disturbing the
enterocytes of the midgut and a lower incidence of necrotic enteritis.
Inovocox EM1 is the optimal choice for environmental or management
conditions that make it challenging for coccidiosis vaccines to be
successful.
“Pfizer Poultry Health created two distinct formulations with broiler
operations in mind,” said Dr. Jon Schaeffer, Director of Veterinary
Operations at Pfizer.
“Because no two operations are the same, veterinarians can help
producers select the best vaccine for the individual conditions and
specific coccidiosis challenge that each unit faces.
“In conditions that favour necrotic enteritis, such as wet litter,
extended brooding, high pH soil, poor ventilation, etc., Inovocox EM1 is
the solution of choice.”
The new vaccine is the perfect partner for the Embrex® Inovoject®
System, which can deliver a precise and uniform dose of either Inovocox
or Inovocox EM1 in ovo to 18- or 19-day-old embryonated chicken
eggs.
The Embrex Inovoject System is the most widely used in ovo system
available because it delivers optimal in ovo vaccination through
adaptable egg location, consistent shell penetration, accurate site of
injection, gentle vaccine delivery and effective needle sanitation.
“In the case of coccidiosis, in ovo administration enables
precise coccidiosis control across the entire flock at the earliest
possible point in a chicken’s life -while it is still in the egg,” Dr.
Schaeffer says. “Coccidiosis is difficult to control once it takes hold
in a flock, making early prevention a priority for poultry producers.
“Acquiring early immunity from Inovocox gives other coccidiosis
management tools a head start in maintaining flock health,” Dr.
Schaeffer says.
In addition, Inovocox EM1and Inovocox are the only coccidiosis vaccines
approved by the USDA to be co-administered in ovo with Marek’s and
bursal disease vaccines. This versatility provides producers with unique
options for immunizing flocks while enhancing feed conversion.
Feed conversion is frequently used to measure the effectiveness of a
coccidiosis control program in broilers, which is why achieving early,
strong and long-lasting immunity with Inovocox vaccines is the key to
high-performing flocks.
About Pfizer Poultry Health
Pfizer Poultry Health, a business unit of Pfizer Animal Health, is a
leading provider of innovative, high-performance poultry health
solutions to the global poultry industry.
Pfizer Poultry Health is committed to delivering reliable products
combined with world-class customer service that the global poultry
industry has grown to depend on to enhance bird performance and improve
poultry operations. For more information about Pfizer Poultry Health,
visit www.pfizerpoultryhealth.com.
All brands are the property of Pfizer Inc., its affiliates and/or its
licensors. ©2011 Pfizer Inc. All rights reserved.
Jessica Beyler Rasmussen
Pfizer Poultry Health
+1 919-314-2631
jessica.rasmussen@pfizer.com